" class="no-js "lang="en-US"> ArisGlobal - Medtech Alert
Thursday, July 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

ArisGlobal

About ArisGlobal

ArisGlobal

ArisGlobal is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® boosts efficiency, ensures compliance and reduces cost through multi-tenant Software-as-a-Service (SaaS) architecture. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China.

Related Story

Mergers & Aquisitions

 ArisGlobal Signs Agreement to Acquire Amplexor Life Sciences | MTA

ArisGlobal Signs Agreement to Acquire Amplexor Life Sciences

March 1 2023

ArisGlobal, the leading provider of life sciences software designed to automate core drug development functions […]

Appointments

 ArisGlobal Accelerates Growth

ArisGlobal Accelerates Growth, Announces Executive Evolution

September 8 2022

 ArisGlobal, the leading provider of life sciences software that automates core drug development functions with […]

Drug Development

 ArisGlobal Announces New Brand Identity for Award-Winning Life Sciences SaaS Platform

ArisGlobal Announces New Brand Identity for Award-Winning Life Sciences SaaS Platform, LifeSphere

July 20 2022

ArisGlobal, the leading provider of life sciences software that automates core drug development with its […]

Industry News

 ArisGlobal Acquires Boehringer Ingelheim’s Signal Analytics Engine

ArisGlobal Acquires Boehringer Ingelheim’s Signal Analytics Engine, Bringing Enhanced and Unmatched Pharmacovigilance Capabilities to Life Sciences Industry

May 12 2022

ArisGlobal, the global market leader in drug safety solutions worldwide, and Boehringer Ingelheim, a leading […]